It's Hair Loss Support At Its Best
One treatment about to enter clinical testing in Europe(France) is low-dose IL-2.
I am curious to see the results of the trail after 1 year.
The artical is published 10 May 2016. If you have reached the maximum number of free premium articles, see the text below.
In a 2014 study, dermatologist Thierry Passeron and colleagues at the University Hospital of Nice, France, reported hair regrowth in four of five patients — each of whom had long-standing, treatment-resistant disease — who were given a four-week course of low-dose IL-2 injections. These results weren’t as celebrated as Christiano and colleagues’ findings because, two patients had more than 50% regrowth, two had regrowth that wasn’t enough to stop them wearing a wig.
Two years on and the trial participants, as well as Passeron, are looking back on the trial more favourably. “We have had no relapses,” says Passeron, “even though treatment stopped after the trial.” Not only did the participants not relapse, but their hair continued to regrow: the two women who still had to wear wigs now have almost complete regrowth; of the others, one has almost complete regrowth and the other has more than 75% regrowth. But, he warns, there may have been a strong placebo effect since people came to hospital for injections for four weeks.
To test the treatment, with funding from the Programme Hospitalier Recherche Clinique (PHRC), Passeron and colleagues are doing a prospective, placebo-controlled randomised trial in 80 patients around France and following them up for one year. They will take blood samples to test a hypotheses supported by biopsies from the five patients in the 2014 open-label study: that the low-dose IL-2 stimulates the activity of T regulator cells that dampen down the damaging T effector cells and reduce the immune infiltrate around the hair follicle. “If our hypothesis is true, and the result is good,” says Passeron, “then, with the impressive JAK inhibitors, I’m hopeful in the coming years that the situation for alopecia patients will improve.”
Hello I am French and I have to meet in September to make the clinical trial, the try(essay) has already begun since December 2015 I had professor Passeron by e-mail he told me that all the people had a complete regrowth and that hair did not fall again since 2013 it is the cure which hard that 4 weeks no side effect I inform you
Thank you Kevin.
Please keep us updated when you start the treatment.
No relapses after stopping the treatment of 4 months sounds very promising.
everyone speak in a dermatologist 's treatment
IL-2 is classified as a "biologic response modifier (BRM)" or "biologic therapy." Interleukin-2 is part of a family of proteins called cytokines. Cytokines act primarily by communicating between the various cells of the body's immune system.
IL-2 has been approved for skin cancer treatment with a high-dose regimen, but it may also be administered in a low-dose form. Low-dose interleukin-2 is usually given as a shot under the skin (subcutaneous injection, SubQ).
Depletion of regulatory T (TReg) cells in otherwise healthy individuals leads to multi-organ autoimmune disease and inflammation. This indicates that in a normal immune system, there are self-specific effector T cells that are ready to attack normal tissue if they are not restrained by TReg cells. The data imply that there is a balance between effector T cells and TReg cells in health and suggest a therapeutic potential of TReg cells in diseases in which this balance is altered. Proof-of-concept clinical trials, now supported by robust mechanistic studies, have shown that low-dose interleukin-2 specifically expands and activates TReg cell populations and thus can control autoimmune diseases and inflammation.
There are ongoing clinical trials with Low-dose IL-2 for treatment of Type 1 Diabetes, Ulcerative Colitis and Alopecia.
The low dose IL-2 is used for treatment of autoimmune diseases. The clinical trial is related to AA.